Lithosun 300 Tablet contains lithium carbonate 300 mg, a mood stabilizer primarily indicated for the treatment and management of bipolar disorder. Lithium carbonate exerts its therapeutic effects by modulating neurotransmitter activity and stabilizing neuronal excitability, thereby reducing the frequency and severity of manic and depressive episodes. It is commonly prescribed for acute mania, maintenance therapy to prevent relapse, and as an adjunct in treatment-resistant depression. The pharmacokinetics of lithium involve renal excretion, necessitating careful monitoring of serum lithium levels to avoid toxicity, which can manifest as tremors, gastrointestinal disturbances, or neurological symptoms. Dose adjustments are often required based on clinical response and serum concentrations, with regular assessment of renal and thyroid function recommended during prolonged therapy. Lithosun 300 should be used cautiously in patients with renal impairment, cardiovascular disease, or electrolyte imbalances. Concomitant use with diuretics, NSAIDs, or ACE inhibitors may increase lithium levels and risk of adverse effects. Patient education on maintaining adequate hydration and adherence to prescribed dosing is essential to optimize therapeutic outcomes and minimize toxicity. Lithosun 300 Tablet represents a cornerstone in mood disorder management, necessitating individualized treatment plans and vigilant clinical monitoring.